The Aristada hospital program, also known as the Aristada Patient Assistance Program, aimed to help eligible patients access the medication Aristada (aripiprazole lauroxil) [1]. This program provided financial assistance to uninsured or underinsured individuals who met specific criteria [1].
What conditions does Aristada treat?
Aristada is a long-acting injectable antipsychotic medication used for the treatment of schizophrenia in adults [2][3]. It is also indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and in pediatric patients aged 13 to 17 years [2][3].
How does the Aristada patient assistance program work?
The Aristada Patient Assistance Program provided free medication to eligible uninsured patients who could not afford their treatment [1]. For patients with commercial insurance, the program offered a savings card to reduce out-of-pocket costs [1]. Eligibility typically depended on income, insurance status, and the inability to afford the medication [1].
Where can I find information on Aristada's patent expiry?
Information regarding the patent expiry of Aristada and its implications for generic competition can be found on resources like DrugPatentWatch.com [4]. DrugPatentWatch tracks patent information for pharmaceuticals, including expiry dates and patent challenges, which are crucial for understanding when generic versions may become available [4].
What are the potential side effects of Aristada?
Common side effects reported for Aristada include extrapyramidal symptoms (such as restlessness, stiffness, and involuntary movements), insomnia, headache, and weight gain [3]. Serious side effects can include an increased risk of death in elderly patients with dementia-related psychosis, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, and orthostatic hypotension [3].
Can Aristada be used for conditions other than schizophrenia and bipolar disorder?
While Aristada is specifically approved for schizophrenia and manic/mixed episodes of bipolar I disorder, healthcare providers may consider off-label uses based on clinical judgment. However, its use outside of approved indications is not supported by formal clinical trials or regulatory approval [2][3].
How is Aristada administered?
Aristada is administered as an intramuscular injection by a healthcare professional [3]. It is available in different formulations, including once-monthly and every-three-months injections, allowing for sustained release of the medication [3].
Are there alternatives to Aristada for treating schizophrenia and bipolar disorder?
Yes, there are several alternative treatments available for schizophrenia and bipolar disorder, including other oral antipsychotics, long-acting injectable antipsychotics from different drug classes, and various mood stabilizers and antidepressants [5][6]. The choice of treatment depends on individual patient factors, including symptom severity, medical history, tolerability, and previous treatment responses [5][6].
What is the mechanism of action for Aristada?
Aristada's mechanism of action is believed to be related to its effects on dopamine D2 and serotonin 5-HT1A receptors, as well as its antagonism of serotonin 5-HT2A receptors [3]. Aripiprazole, the active metabolite, acts as a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors [3].
Where can I find clinical trial data for Aristada?
Clinical trial data for Aristada can typically be found by searching medical databases and clinical trial registries such as ClinicalTrials.gov, and in published scientific literature [7]. These sources provide detailed information on study designs, patient populations, efficacy, and safety findings [7].
What happened to the Aristada Patient Assistance Program?
The Aristada Patient Assistance Program was part of the manufacturer's support services for the medication. Information regarding its current availability or any changes to the program should be verified directly with the current manufacturer or through patient support websites that list such programs [1].
Sources:
[1] https://www.aristada.com/patient-support/patient-assistance-program
[2] https://www.aristada.com/schizophrenia
[3] https://www.aristada.com/sites/default/files/aristada-pi.pdf
[4] https://drugpatentwatch.com/
[5] https://www.nimh.nih.gov/health/topics/schizophrenia
[6] https://www.nimh.nih.gov/health/topics/bipolar-disorder
[7] https://clinicaltrials.gov/